An interventional study of Mobile Teleconsultation Arm (MTA) and Outpatient Consultation Arm (OCA) in Acne, sponsored by Medical University of Graz. Completed at 1 site in Austria. Open to participants aged 12 Years to 30 Years. Per ClinicalTrials.gov, last updated 2014-01-14.
Sponsored by Medical University of Graz · Not applicable, Interventional, and Health services research
The purpose of the present study is to determine whether a mobile teledermatology care model can achieve better clinical outcomes as compared to conventional, outpatient care for the management of severe acne treated with isotretinoin.
The superiority of mobile care in comparison to conventional, outpatient care will be investigated regarding
730 studies on the registry are indexed under Acne Vulgaris; 86 are open to participants now.
This study's enrollment of 69 is close to the median of 69 across 628 interventional studies indexed under Acne Vulgaris.
Browse Acne Vulgaris studies →Medical University of Graz is the lead sponsor of 459 studies on the registry; 98 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Female or male, aged 12 to 30 years
Exclusion Criteria:
Conventional in Office Care
Other: Outpatient Consultation Arm (OCA)
Mobile Teledermatology Care
Other: Mobile Teleconsultation Arm (MTA)
In addition to a face-to-face visit at baseline, patients will conduct "mobile visits" at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines.
Also known as: MTA, Health Care Service Modality
Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.
Also known as: OCA, Health Care Service Modality
Global evaluation Acne score (GEA)
Change from Baseline in the median GEA score at week 24
Time frame: week 24
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Graz